… to evaluate the efficacy and safety of anlotinib treatment in … similar efficacy comparing with
the phase 3 trial of anlotinib. … half of patients (46.6%) were more than third lines of anlotinib …

… presents an important way to obtain patient data that cannot be obtained … safety and
adverse events. Citation7 In this study, we analyzed the efficacy and safety of anlotinib in patients …

… patients treated with anlotinib was 5 months, with patients … In another study of 52 NSCLC
patients receiving anlotinib as … rates in patients with ECOG PS 0–1 and patients without liver …

… efficacy and safety of anlotinib remains uncertain. The results of this study show that anlotinib
is effective in patients … , have demonstrated the efficacy and safety of anlotinib for the first …

… performed, is safe, and can increase patient tolerance (19). In this study, 150 patients with
advanced NSCLC were treated with anlotinib, and the efficacy and safety of the treatment …

… The aim of this study was to investigate the efficacy and safety of anlotinib for patients
with … regimens in real world situations and the preliminary analysis of an efficacy predictor. …

… efficacy and safety of anlotinib when used alone or with other antineoplastic agents in patients
… In this study, the survival of treatment-naïve patients with aNSCLC who received anlotinib …

… Results: Of 167 patients were enrolled in this study, 106 were in Anlotinib … patients (P <
0.05- can be a specific value). There was a significant difference in DCR between the anlotinib …

… efficacy was evaluated for all 109 patients enrolled in this study. A total of 35 patients received
anlotinib … A total of 39 patients received anlotinib as second-line treatment with an overall …

… was 5.4 months, while in this study, as mentioned above, the median PFS of patients
treated with anlotinib combined with immunotherapy reached 6.7 months, and the addition of …